Farooqui, Mohammed Z. H.

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia

Ahn, I. E., Underbayev, C., Albitar, A., Herman, S. E. M., Tian, X., Maric, I., Arthur, D. C., Wake, L., Pittaluga, S., Yuan, C. M., et al. (2017) · Blood

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 341

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

Ahn, I. E., Farooqui, M. Z. H., Tian, X., Valdez, J., Sun, C., Soto, S., Lotter, J., Housel, S., Stetler-Stevenson, M., Yuan, C. M., et al. (2018) · Blood

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 205

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy

Landau, D. A., Sun, C., Rosebrock, D., Herman, S. E. M., Fein, J., Sivina, M., Underbayev, C., Liu, D., Hoellenriegel, J., Ravichandran, S., et al. (2017) · Nature Communications

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 176

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

Sun, C., Nierman, P., Kendall, E. K., Cheung, J., Gulrajani, M., Herman, S. E. M., Pleyer, C., Ahn, I. E., Stetler-Stevenson, M., Yuan, C. M., et al. (2020) · Blood

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 103

Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE‐023 study

Mateos, M., Orlowski, R. Z., Ocio, E. M., Rodríguez‐Otero, P., Reece, D., Moreau, P., Munshi, N., Avigan, D. E., Siegel, D. S., Ghori, R., et al. (2019) · British Journal of Haematology

Multiple Myeloma Research and TreatmentsMultiple Sclerosis Research Studies

Cited by 73